Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals - RGEN News | RalliesRepligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals
R
RGEN• Repligen-BioLife deal update
- Repligen agreed to acquire BioLife Solutions, expanding its footprint in cell therapy tools and biopreservation media.
- The deal was announced July 22.
- Closing is expected in the fourth quarter, subject to regulatory and shareholder approvals.
- Until closing, the two companies will continue to operate as separate, independent businesses.
DNTH
•
